Dr. Deborah A. Elder, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- Medical school
- University of Kentucky College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Kentucky College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
OH license 35079609
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital Medical Center (711 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 6 companies reported 6 payments worth $662 in total to this clinician.
| Beta Bionics, Inc. | $148 |
|---|---|
| Sanofi-aventis U.S. LLC | $142 |
| Medtronic, Inc. | $133 |
| Mannkind Corporation | $118 |
| Sequel Med Tech, LLC | $93.93 |
| Tandem Diabetes Care, Inc. | $26.95 |
| Food and Beverage | $662 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $44,391 in research payments for these studies, mostly to the institutions running them.
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Genzyme Corporation · Active, not recruiting · NCT06111586
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.